Fujun Yang

Weihai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.

Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.

Journal: Future oncology (London, England)
Published: October 30, 2025

Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a case report.

Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a case report.

Journal: Frontiers in oncology
Published: May 30, 2025

Correction: Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.

Correction: Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.

Journal: BMC medicine
Published: February 12, 2025

Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.

Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.

Journal: BMC medicine
Published: May 09, 2024

Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.

Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.

Journal: Frontiers in oncology
Published: January 12, 2024

Opportunistic Screening With Low-Dose Computed Tomography and Lung Cancer Mortality in China.

Opportunistic Screening With Low-Dose Computed Tomography and Lung Cancer Mortality in China.

Journal: JAMA network open
Published: December 12, 2023

Predicting lung cancer survival prognosis based on the conditional survival bayesian network.

Predicting lung cancer survival prognosis based on the conditional survival bayesian network.

Journal: BMC medical research methodology
Published: July 05, 2022

Pyrotinib for HER2-amplified non-small cell lung cancer patient after progression to Afatinib: a case report.

Pyrotinib for HER2-amplified non-small cell lung cancer patient after progression to Afatinib: a case report.

Journal: Anti-cancer drugs
Published: March 24, 2022

SMARCA2 deficiency in NSCLC: a clinicopathologic and immunohistochemical analysis of a large series from a single institution.

SMARCA2 deficiency in NSCLC: a clinicopathologic and immunohistochemical analysis of a large series from a single institution.

Journal: Environmental health and preventive medicine
Published: March 15, 2022

A Prognostic Model of Non-Small Cell Lung Cancer With a Radiomics Nomogram in an Eastern Chinese Population.

A Prognostic Model of Non-Small Cell Lung Cancer With a Radiomics Nomogram in an Eastern Chinese Population.

Journal: Frontiers in oncology
Published: November 17, 2021

Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma.

Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma.

Journal: Frontiers in oncology
Published: April 10, 2021

Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma.

Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma.

Journal: Neoplasia (New York, N.Y.)
Published: March 30, 2021
Showing 1-12 of 13

Last Updated: 09/26/2026